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Objective: To assess methods to calculate achieving and sustaining remission in a double blind
randomised trial in patients with RA who received etanercept, methotrexate, or an etanercept/
methotrexate combination.
Methods: Remission was defined as DAS,1.6, DAS28,2.6, and ACR70 response. Sustaining remission
was analysed in three ways: (a) analysis of sustained DAS remission, DAS28 remission, or ACR70
response continuously for 6 months; (b) analysis of sustained remission appraised through a continuity
rewarded scoring system, which is the weighted sum of all intervals in the study in which patients are in
DAS or DAS28 remission; or (c) longitudinal modelling of remission odds using generalised estimating
equations.
Results: Significantly more patients treated with the etanercept/methotrexate combination reached DAS
remission (37%) than those treated with either methotrexate (14%) or etanercept (18%) alone (p,0.01).
Results for DAS28 and for the ACR70 response were similar. Agreement between DAS remission and
DAS28 remission was good, but agreement between either of these and the ACR70 response was less.
Patients in DAS or DAS28 remission had a lower level of disease activity (fewer active joints, lower ESR)
than those achieving ACR70 response; the converse was seen using pain VAS. The three methods were
comparable for sustainability of remission and showed significant advantage for combination therapy,
which increased the number and durability of remission periods.
Conclusions: DAS and DAS28 remission results were similar for assessing achieving and sustaining
remission in RA, frequently differing from patients classified as ACR70 responders. The three methods of
examining duration of remission produced comparable results.
R
heumatoid arthritis (RA) is associated with significant
morbidity, mortality, and healthcare expenditure.1–4
Remission of disease activity has been considered to be
the ultimate goal of treatment in RA. A subcommittee of the
American Rheumatism Association (ARA) published a set of
preliminary criteria for clinical remission as early as 1981,
signifying the importance of this end point.5 These criteria,
however, have not been widely used and instead it has been
suggested that remission based on the disease activity score
(DAS) or on the DAS28 with limited joint counts should be
used.6 Some people suggest the American College of
Rheumatology (ACR) 70 as a surrogate for remission, but
remission is a definition of a status, whereas ACR70 is an
assessment of response, regardless of the final value. An
important aspect in the definition of remission is time: being
in remission is much more important if it is sustained over a
period of time.
Since the early 1980s there have been significant advances
in treatment paradigms for RA, including the use of pulse
weekly methotrexate (MTX) and anti-tumour necrosis factor
agents.7 8 Despite these advances, a universally accepted
method of assessing remission in RA has not been defined.
One possible explanation is that traditional agents are either
too toxic or induce remission in too few patients to allow for a
meaningful comparison of methods; thus, achievement of
remission was considered to be too high a hurdle to overcome
for the vast majority of patients.
At present, three composite end points, which are reported
to perform similarly, are widely used to evaluate disease
activity: the ACR response criteria (ACR20, ACR50, and
ACR70), the DAS, and the DAS28.9–11 Owing to difficulties in
application of the ACR remission criteria (inclusion of fatigue
and a time requirement of 2 months), most recent trials have
used a DAS based definition. These have been shown to
correlate well with the ACR definition,6 although recent
findings indicate that the DAS28 definition may be too
‘‘lenient’’ (that is, closer to low disease activity than
remission).12 Although ACR response criteria have not been
used to define remission, achieving an ACR70 response has
been used as an indicator of significant control of disease
activity.13
In addition to defining a specific cut off point required to
achieve remission, the durability of remission is important
and needs to be examined. The draft criteria proposed by the
ARA included a requirement for a minimum of 2 months in
remission5; however, this duration was somewhat arbitrary
and chosen primarily because 90% of patients considered to
be in remission fulfilled this criterion.5 13 The American Food
and Drug Administration (FDA) requires maintaining an
Abbreviations: ACR, American College of Rheumatology; ARA,
American Rheumatism Association; ConRew, continuity rewarded; DAS,
Disease Activity Score; ESR, erythrocyte sedimentation rate; FDA, Food
and Drug Administration; GEE, generalised estimating equations; IQR,
interquartile range; LOCF, last observation carried forward; MTX,
methotrexate; OR, odds ratio; RA, rheumatoid arthritis; RCT,
randomised controlled trial; TEMPO, Trial of Etanercept and
Methotrexate with radiographic Patient Outcomes; VAS, visual analogue
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ACR70 response for at least 6 months to consider a patient to
have achieved a major clinical response.14 No time component
was added to the DAS based remission criteria. A recently
proposed method rewards durability of remission by counting
the number of periods of remission (length of period defined
a priori) and adding extra weight to consecutive periods in
remission (continuity rewarded, ConRew score).15
This report aims at examining various ways of assessing
remission in a comparative, randomised controlled trial
(RCT) of a relatively large number of patients treated with
highly effective treatments for 1 year. This allowed a mean-
ingful evaluation and comparison of these methods.
METHODS
This study was conducted in accordance with the Declaration
of Helsinki. We analysed the data from the TEMPO (Trial of
Etanercept and Methotrexate with radiographic Patient
Outcomes),8 which was a multicentre, double blind, parallel
design study of adult patients with active RA randomised to
one of three treatment groups: etanercept only (25 mg twice
weekly), MTX only (7.5 mg escalated to 20 mg weekly), or
etanercept and MTX in combination.
Clinical assessments, including complete joint counts,
erythrocyte sedimentation rate (ESR), C reactive protein,
pain visual analogue scale (VAS), general health VAS, Health
Assessment Questionnaire, and physician and patient global
assessments, were performed at regular intervals.
Dose administration
In addition to the test drugs, all patients received folic acid
supplementation of 5 mg twice weekly. Patients were
allowed stable doses of oral corticosteroids ((10 mg/day of
prednisone or equivalent) and one non-steroidal anti-
inflammatory drug; disease modifying antirheumatic drugs
were not allowed.
Definitions of remission
DAS and DAS28 were calculated as described previously
using the Ritchie Articular Index and 44 swollen joint count
or the 28 joint count for tender and for swollen joint count,
respectively.9 10 Remission was defined as DAS ,1.6 or as
DAS28 ,2.6. Table 1 lists the specific joints used in
calculating the ACR response, DAS, and DAS28. Remission
based on the recommendations of the ARA5 was not
calculated because fatigue was not evaluated in this study.
Although the initial ACR response criteria suggested assess-
ment of 68 joints, it was recognised that alternatives could be
used, if they are proved to have equal discriminative power.16
In this study all of the 71 joints assessed were used to
calculate the ACR response rates.
Assessment of sustained remission
Continuity rewarded scoring
The extent of continuing remission (based on DAS and
DAS28) was appraised by the ConRew scoring system, a
weighted sum of DAS and DAS28 remission scores for all
intervals in the study.15 A score of 0 was assigned for non-
remission at a given time point and a value of 1 was assigned
for remission. The ConRew was changed from 1 to 2 if an
interval in remission was followed by a second interval in
remission. If a patient was in remission at the final interval,
that interval was also given a value of 2. There were 10
intervals of 4 weeks or longer with DAS and DAS28 scores
after baseline, leading to a possible maximum ConRew score
of 20. One visit 2 weeks after baseline was not included to
avoid a potential bias against the MTX treatment group.
Comparing the unweighted sum of periods with the ConRew
score allows one to distinguish overall length of remission
time and durability.
Generalised estimating equations (GEE)
Remission status over time was also evaluated using the
generalised estimating equations (GEE) approach for long-
itudinal models. GEE models adjust for within-patient
correlations between time points and produce estimates of
time averaged odds ratios (ORs) for binomial data. In
addition, GEE models do not require complete data and can
be fitted when subjects do not have observations at all time
points.17
Major clinical response and sustained DAS or DAS28
remission for 6 months
Major clinical response was calculated as an ACR70 response
continuously for at least 6 months as suggested by the FDA.
For comparison, we also calculated the percentage of patients
who maintained DAS or DAS28 remission for 6 months.
Table 1 Joints assessed for DAS, DAS28, and ACR
response in the TEMPO trial
Joint
ACR
response DAS DAS28
Temporomandibular joints (n = 2) X X*
Sternoclavicular joints (n = 2) X X
Acromioclavicular joints (n = 2) X X
Shoulders (n = 2) X X X
Elbows (n = 2) X X X
Wrists (n = 2) X X X
Metacarpophalangeal joints (n = 10) X X X
Cervical spine (n = 1) X* X*
Distal interphalangeal joints (n = 8) X
Hips (n = 2) X* X*
Knees (n = 2) X X X
Ankles (n = 2) X X
Talocalcaneal (n = 2) X X*
Tarsi (n = 2) X X*
Metatarsophalangeal joints (n = 10) X X
Fingers (proximal interphalangeal joints)
(n = 10)
X X X
Toes (n = 10) X
*Counted for pain assessment (Ritchie articular index and ACR response)
but not for swelling.
Table 2 Concordance between DAS remission, DAS28
remission, and ACR70 response at week 52
ACR70
DAS
remission
DAS
baseline
(median
DAS
baseline
.median Total
No No 121 167 288 (57%)
No Yes 32 13 45 (9%)
Yes No 33 43 76 (15%)
Yes Yes 70 30 100 (20%)
ACR70
DAS28
remission
DAS
baseline
(median
DAS
baseline
.median Total
No No 118 170 288 (57%)
No Yes 35 10 45 (9%)
Yes No 32 37 69 (14%)
Yes Yes 71 36 107 (21%)
DAS
remission
DAS28
remission
DAS
baseline
(median
DAS
baseline
.median Total
No No 136 197 333 (65%)
No Yes 18 13 31 (6%)
Yes No 14 10 24 (5%)
Yes Yes 88 33 121 (24%)
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Statistical analysis
Except where otherwise stated, all statistical tests were two
sided and significance was assessed at the a=0.05 level.
Unless otherwise mentioned, efficacy analysis used the last
observation carried forward (LOCF) imputation approach to
include all patients in the time point analysis. ConRew data
were appraised by Kruskal-Wallis tests.
RESULTS
A total of 682 patients received the study drugs (MTX=228,
etanercept=223, etanercept + MTX=231). Study partici-
pants were predominantly women and white with a mean
age of 52.9 years. Treatment groups were well balanced for
demographic and baseline disease characteristics.8
End point criteria
The percentages of patients achieving DAS remission at week
52 were 37%, 18%, and 14% and achieving DAS28 remission
were 38%, 18%, and 17%, for the combination, etanercept and
MTX, groups, respectively. Combination therapy was sig-
nificantly better than either of the monotherapies (p,0.01)
for both DAS and DAS28 remission. A significantly greater
percentage of patients given combination therapy achieved
ACR70, compared with the etanercept and methotrexate
groups (43%, 24%, and 19%, respectively; p,0.05).
To better understand the relationship between ACR70,
DAS remission, and DAS28 remission, and to evaluate the
effect of baseline disease activity on this relationship, we
calculated the concordance rates stratified for baseline level
of disease activity (table 2). Overall discordance was greater
between either DAS or DAS28 and the ACR70 response, 24%
and 22%, respectively, than between DAS and DAS28 (11%).
Similarly, concordance, as measured by the k coefficient, was
greater between DAS and DAS28 remission (k=0.74) than
between the ACR70 response and either DAS or DAS28
remission (k=0.45, 0.49, respectively). It was easier to reach
an ACR70 response than DAS or DAS28 remission, primarily
in patients with high baseline disease activity. In patients
with high baseline disease activity discordance between
ACR70 and DAS was seen in 56 patients. The majority (43)
showed a response according to ACR70 but not according to
DAS. By contrast, in the other patients with a lower baseline
disease activity, discordance was equally distributed, with
roughly 50% meeting either ACR70 or DAS criteria. A similar
Figure 2 Swollen joint count distribution among patients in DAS
remission, DAS28 remission, and fulfilling ACR70 response. Mean (SD)
swollen joint count for DAS remission, DAS28 remission, and ACR70
responders were 0.8 (1.6), 0.8 (1.6), and 1.1 (1.8), respectively.
Medians (25%–75% IQR) for DAS remission, DAS28 remission, and
ACR70 responders were 0 (0–1), 0 (0–1), and 0 (0–2), respectively.
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Figure 3 Erythrocyte sedimentation rate (ESR) for individual patients in
DAS remission, DAS28 remission, and fulfilling ACR70 response,
ordered from the lowest to the highest value and expressed as the
cumulative probability. Means (SD) for DAS remission, DAS28
remission, and ACR70 responders were 13.6 (10.5), 11.2 (7.3), and
17.7 (14.4), respectively. Medians (25%–75% IQR) for DAS remission,
DAS28 remission, and ACR70 responders were 11 (6–18), 10 (6–16),
and 14 (8–22), respectively.
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Figure 4 Pain visual analogue scale (VAS) for patients in DAS
remission, DAS28 remission and fulfilling ACR70 response, ordered
from the lowest to the highest value and expressed as the cumulative
probability. Means (SD) for DAS remission, DAS28 remission, and
ACR70 responders were 11.5 (12.3), 11.8 (11.3), and 9.0 (8.6),
respectively. Medians (25%–75% IQR) for DAS remission, DAS28
remission, and ACR70 responders were 8.0 (2–17), 10 (2–18), and
8 (2–13), respectively.
Figure 1 Tender joint count distribution among patients in DAS
remission, DAS28 remission, and fulfilling ACR70 response. Mean (SD)
tender joint counts for DAS remission, DAS28 remission, and ACR70
responders were 0.4 (1.2), 1.2 (2.4), and 1.8 (2.5), respectively.
Medians (25%–75% interquartile range (IQR)) for DAS remission,
DAS28 remission, and ACR70 responders were 0 (0–0), 0 (0–2), and
1 (0–3), respectively.
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pattern is seen for the comparison of ACR70 and DAS28. In
addition, as expected, we found that patients with low
baseline DAS had a better chance of reaching DAS or DAS28
remission than those with high baseline DAS.
We further characterised the disease activity status of
patients who were ACR70 responders or were in DAS or
DAS28 remission, using four single measures of disease
activity at week 52: tender joint counts, swollen joint counts,
ESR, and pain VAS (figs 1–4, respectively). From these plots,
it is evident that the ACR70 responders included more
subjects with a high number of tender and swollen joints and
a higher ESR than subjects in DAS or DAS28 remission. The
differences between those in remission by DAS and DAS28
were less pronounced, although a higher percentage of
patients in DAS remission had no painful joints than those
in DAS28 remission. A different pattern was seen when a
subjective measure of disease activity, patient’s assessment of
pain (VAS), was used (fig 4). Patients who were ACR70
responders reported less pain, followed in increasing order by
those in DAS remission and DAS28 remission.
Sustained remission criteria
Several methods of assessing remission over a period of time
are presented here. The ConRew analysis was used to see if it
could produce results that are consistent with other clinical
end points in an RCT.15 Both the unweighted sum scores and
the ConRew scores followed a highly skewed distribution,
with most patients experiencing only one or a few periods of
remission (table 3). Nevertheless, ConRew analysis was able
to differentiate between the treatment groups and showed
results consistent with those reported for the week 52 time
point. Comparing the ConRew scores with the unweighted
scores shows that the combination group gained in both
number of periods and durability. For example, the MTX
group had a mean 1.0 DAS remission periods of 4 weeks or
longer, and a mean bonus of 0.7. The results of the etanercept
group were only slightly better. In contrast, the combination
group had a mean 2.4 periods of remission, and a mean
bonus of 2.0 (table 3). Furthermore, the differentiation
between the treatment groups using DAS were very close to
that obtained using DAS28, further adding to the validity of
this measurement as a way of expressing remission that is
persistent over time. Also in this analysis, the scores for
ConRew based on DAS28 compared with DAS for each
treatment group were higher, indicating that the DAS28
defines remission less strictly.
The major clinical response was also able to differentiate
the three treatment groups (table 4). Additionally, there was
relatively more separation between the combination therapy
and etanercept or MTX monotherapy arms than that reported
with the ACR70 at one time point, implying that this measure
might be more useful than end point measures for comparing
highly effective treatments. When the same 6 month dura-
tion of response was applied to DAS and DAS28 remission,
similar results were seen for discrimination between the
groups, compared with end point criteria (table 4).
A third method examining remission that also includes
time was the use of longitudinal modelling, in this case
employing GEE. The odds of achieving remission were
significantly higher for the combination group than for
either of the two monotherapy groups (table 5). To confirm
that various methods of imputation for missing information
have no notable effect on the outcomes of GEE analysis, we
evaluated three different methods for handling missing data
and found that in the TEMPO trial equivalent results were
obtained regardless of whether (a) no data adjustments were
made; (b) all missing time points were assigned a ‘‘not in
remission’’ value; or (c) an LOCF method was used (table 5).
DISCUSSION
We have closely examined the usefulness of several measures
of RA disease activity and disease response in relation to
remission using an RCT. We examined two overall
approaches to defining remission in an RCT: remission
achieved at one time point, cross sectional (in this case,
week 52 time point) versus remission criteria that incorporate
time as a factor. The cross sectional criteria were further
analysed to identify the concordance/discordance rates, the
contribution of baseline disease activity to these measures,
and the characteristics of patients satisfying each definition
Table 3 Unweighted sum scores of 4 week or longer remission periods and ConRew
scores for DAS and DAS28
Treatment No
Unweighted sum score ConRew score
Mean (SD) Median (range) Mean (SD) Median (range)
DAS
MTX 228 1.0 (2.0) 0 (0–9) 1.7 (3.8) 0 (0–18)
ETN 223 1.1 (2.2) 0 (0–9) 1.9 (4.0) 0 (0–18)
MTX + ETN 231 2.4 (3.1) 1 (0–10) 4.4* (6.0) 1 (0–20)
DAS28
MTX 228 1.0 (2.0) 0 (0–9) 1.7 (3.6) 0 (0–18)
ETN 223 1.2 (2.3) 0 (0–9) 2.1 (4.2) 0 (0–18)
MTX + ETN 231 2.6 (3.1) 1 (0–10) 4.8* (6.1) 0 (0–20)
*p,0.0001 v MTX and etanercept (ETN) monotherapy.
Table 4 Number (%) of patients achieving sustained response over 6 months
Variable
Methotrexate Etanercept
Etanercept +
methotrexate
p Value(n = 228) (n = 223) (n = 231)
Major clinical response* 13 (5.7) 22 (9.9) 55 (23.8) ,0.0001
Sustained DAS remission 14 (6.1) 13 (5.8) 39 (16.9) ,0.0001
Sustained DAS28 remission` 8 (3.5) 12 (5.4) 41 (17.9) ,0.0001
*ACR70 response continuously for 6 months; DAS remission continuously for 6 months; `DAS28 remission
continuously for 6 months.
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of remission. Remission that includes a time factor was
assessed using three distinct analytical methods to identify
reproducibility of outcomes compared with the overall
findings of this study.
We found that the two validated cross sectional definitions
of disease remission, based on DAS and DAS28, were similar
(concordance rate of 88%). However, in most of the
comparisons between DAS remission and DAS28 remission,
the DAS definition of remission was slightly stricter than the
DAS28 criterion. This is also in agreement with a recent
publication comparing DAS and DAS28 with the ARA
definition of remission.18 The concordance rate between
these measures was not significantly affected by the baseline
disease activity level of patients.
We found that the concordance between ACR70 response
and DAS (or DAS28) remission was relatively low, especially
in patients who have a high level of baseline disease activity.
Further characterisation of patients fulfilling one of these
three response criteria indicated that patients achieving an
ACR70 response at one time point (week 52) were still at a
higher level of disease activity at that time point, as assessed
by three objective measures of disease activity—swollen and
tender joint counts and ESR—than patients achieving a DAS
or DAS28 remission. This verifies the notion that the ACR70
response is not a good measure for identifying patients in
remission, who by definition should have a very low level of
disease activity. The converse was seen when patients’
assessment of pain (VAS) was studied. The reason for the
discrepancy between the three objective measures and pain
VAS is not clear but might be due to a selection of trial
patients based on tender and swollen joint count as well as
ESR, rather than on pain. A 70% reduction in variables with
relatively high values at baseline still results in relatively high
values at the end point while meeting the ACR70.
Because RA is a chronic disease that requires treatment
over a long period of time, establishment of remission over
time is more meaningful than remission at just one time
point. We evaluated three methods to assess remission using
criteria that incorporate a time factor in defining remission.
ConRew is a method of assessing remission that ‘‘awards’’
points for sustained remission. It does not require patients to
be in remission for any prespecified period of time and thus
can be applied to studies with short or long duration of
treatment. Because the points, both the unweighted sum and
the ConRew score, are directly proportional to the—arbi-
trary—number of visits when disease activity is assessed, the
absolute score is meaningless, and could vary from one study
to another. This is not a problem within one trial where all
groups are assessed with the same frequency. However,
before the ConRew score can be usefully applied in clinical
care, we need to study what minimum period spent in
remission is clinically relevant—that is, translates into better
long term outcome—for example, less joint damage or better
function. Rheumatologists will need to agree on the mini-
mum period of remission that can be considered clinically
relevant. Until such agreement is reached, the method is
useful for comparing treatment arms in one RCT.
In the TEMPO trial, in which a combination of etanercept
and MTX resulted in a significantly higher level of disease
control, the ConRew data could clearly distinguish this group
from the monotherapy arms. Comparing the ConRew score
with the unweighted sum score allowed insight into the
dynamics of the remission, and showed that the combination
group gained in both total remission time and durability of
remission. Although the results of this trial for remission
experience are notable, our analysis also shows we still have a
long way to go: a median of 1 indicates that only 50% of
patients in the combination group had one or more remission
periods lasting 4 weeks or longer. Disregarding skewness of
the mean would indicate that no more than 25% of time in
the trial was spent in remission, often in non-contiguous
periods.
We also evaluated the usefulness of major clinical response
advocated by the FDA. For comparison purposes we applied
the same time requirement to DAS and DAS28 remission. All
three measures of sustained response could clearly distin-
guish the combination arm from the two monotherapy arms.
As expected, the percentages of patients achieving this level
of response were lower than the percentages achieved when
response at one time point is the basis for defining remission.
It should be noted that use of a prespecified time interval
(like 6 months) limits the usefulness of this instrument to
studies of longer duration. Additionally, in studies with
longer duration of treatment, relatively higher numbers of
patients have a chance of achieving a sustained remission
compared with those with a shorter duration of treatment.
Using a prespecified period of 6 months applied to DAS or
DAS28 remission is a less sophisticated method of assessing
remission that produces results consistent with ConRew, and
can potentially be useful in some clinical studies, despite the
mentioned shortcomings.
Finally, we employed a more complex model, GEE, for
assessment of remission that includes a time factor in
calculating the effect of treatment. This analysis method
can be applied to studies of various lengths because it does
not require a prespecified duration of remission. It is also a
powerful method that does not require imputation for
missing data. In the TEMPO trial, the results of this analysis
(OR) were similar in each treatment group regardless of the
imputation method used, going from one extreme (no
adjustment) to another (non-response imputation).
Molenaar et al found that patients in clinical remission,
defined according to the modified ARA criteria, still showed
radiographic progression during a 2 year follow up, although
to a lesser extent than patients having an exacerbation.19 In
fact, they advocated the use of radiographs as one of the
Table 5 Longitudinal modelling of remission time-averaged odds ratios (ORs) using
generalised estimating equations (GEE) for DAS and DAS28, week 8 through 52
Imputation method Combination v MTX Combination v ETN ETN v MTX`
DAS remission
None 3.26 (2.15 to 4.93) 2.57 (1.72 to 3.84) 1.26 (0.86 to 1.99)
LOCF 3.37 (2.26 to 5.04) 2.58 (1.75 to 3.79) 1.31 (0.84 to 2.03)
Non-response* 3.49 (2.34 to 5.20) 2.31 (1.58 to 3.37) 1.51 (0.98 to 2.33)
DAS28 remission
None 3.70 (2.44 to 5.61) 2.56 (1.75 to 3.75) 1.45 (0.92 to 2.27)
LOCF 3.45 (2.36 to 5.06) 2.60 (1.78 to 3.77) 1.33 (0.87 to 2.05)
Non-response* 3.78 (2.62 to 5.46) 2.67 (1.86 to 3.82) 1.42 (0.94 to 2.14)
Results are shown as OR (95% CI).
*Non-response imputation assigns all missing time point values as not in remission; p,0.0001; `not significant.
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criteria for defining remission. It might be worthwhile to
perform a separate remission-type analysis of the 2 year
dataset of the TEMPO trial, taking radiographic progression
into account.
In conclusion, we provide supportive data from a com-
parative RCT of RA that compares various ways of defining
remission. It was found that in this particular RCT all of these
instruments have good discriminative power.
Our data show that DAS remission is the strictest criterion
for remission currently used in clinical trials and that an
ACR70 response should not be used as a surrogate for
remission. We also showed that it is feasible to take time into
consideration, leading to even more meaningful data. In this
respect, the ConRew method proved to be a valid method,
with the advantage that it can be applied to trials of various
duration.
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